Viusid, a nutritional supplement, in combination with interferon α‐2b and ribavirin in patients with chronic hepatitis C

Vilar‐Gomez, Eduardo; Oramas, Bienvenido Grá; Soler, Enrique Arús; Navarro, Raimundo Llanio; Domech, Caridad Ruenes

doi:10.1111/j.1478-3231.2006.01411.x

Cited by 11 publications

(6 citation statements)

References 56 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent trial has suggested that viusid therapy combined with SOC in patients with chronic hepatitis C may reduce inflammation and fibrosis, irrespective of virological response 32. Another recently published study has reported a dual role to explain possible mechanisms of action of viusid on liver histology 33.…”

Section: Discussionmentioning

confidence: 99%

“…Encouraging effects of viusid on liver histology have been reported in patients with non-alcoholic fatty liver disease and chronic hepatitis C 31 32. The authors reported that the addition of viusid to the conventional interferon/ribavirin therapy was associated with significant histological and biochemical improvements, especially in patients without a sustained virological response.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial

et al. 2011

View full text Add to dashboard Cite

ObjectivesViusid is a nutritional supplement with recognised antioxidant and immunomodulatory properties which could have beneficial effects on cirrhosis-related clinical outcomes such as survival, disease progression and development of hepatocellular carcinoma (HCC). This study evaluated the efficacy and safety of viusid in patients with HCV-related decompensated cirrhosis.DesignA randomised double-blind and placebo-controlled study was conducted in a tertiary care academic centre (National Institute of Gastroenterology, Havana, Cuba). The authors randomly assigned 100 patients with HCV-related decompensated cirrhosis to receive viusid (three oral sachets daily, n=50) or placebo (n=50) during 96 weeks. The primary outcome of the study was overall survival at 96 weeks, and the secondary outcomes included time to disease progression, time to HCC diagnosis, time to worsening of the prognostic scoring systems Child–Pugh and Model for End-Stage Liver Disease, and time to a new occurrence or relapse for each one of the main clinical complications secondary to portal hypertension at 96 weeks.ResultsViusid led to a significant improvement in overall survival (90%) versus placebo (74%) (HR 0.27, 95% CI 0.08 to 0.92; p=0.036). A similar improvement in disease progression was seen in viusid-treated patients (28%), compared with placebo-treated patients (48%) (HR 0.47, 95% CI 0.22 to 0.89; p=0.044). However, the beneficial effects of viusid were wholly observed among patients with Child–Pugh classes B or C, but not among patients with Child–Pugh class A. The cumulative incidence of HCC was significantly reduced in patients treated with viusid (2%) as compared with placebo (12%) (HR 0.15, 95% CI 0.019 to 0.90; p=0.046). Viusid was well tolerated.ConclusionsThe results indicate that treatment with viusid leads to a notable improvement in overall clinical outcomes such as survival, disease progression and development of HCC in patients with HCV-related decompensated cirrhosis.Trial registration numberhttp://ClinicalTrials.gov (NCT00502086).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Encouraging effects of Viusid on liver histology have been reported in patients with chronic hepatitis C treated with unmodified interferon and ribavirin 31 . The mechanisms responsible for explaining the effect of Viusid on liver histology remain unknown.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, Vilar Gomez et al. 31 evaluated the efficacy and safety of Viusid in combination with interferon alpha‐2b and ribavirin in patients with chronic hepatitis C. The authors reported that the addition of Viusid to the conventional interferon/ribavirin therapy was associated with significant histological and biochemical improvements, especially in patients without sustained virological response. They suggested that the Viusid‐related effect on histological features, especially fibrosis, appears to be associated with hepatoprotective or antioxidant properties.…”

Section: Introductionmentioning

confidence: 99%

Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease

Vilar‐Gomez¹,

Miranda

Oramas³

et al. 2009

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Its formulation comprises licorice extract, several vitamins such as ascorbic acid or B group vitamins or amino acids ( 5 ). This combination has demonstrated to improve clinical outcomes in several scenarios, such as patients with chronic hepatitis C that did not respond to standard antiviral treatments or interferon therapy ( 4 , 6 ), cirrhotic patients who have failed to achieve sustained virological response with standard of care treatments ( 5 ) or in combination with diet and exercise, to improve fatty liver disease ( 7 ). However, the mechanism of action of VS has not been fully elucidated, and research in this direction could potentiate its application to different pathologies.…”

Section: Introductionmentioning

confidence: 99%

Ocoxin oral solution demonstrates antiviral properties in cellular models

2021

View full text Add to dashboard Cite

Ocoxin Oral Solution (OOS) and Viusid (VS) are nutritional supplements that include several natural products which affect different cellular functions, such as proliferation or the redox status. In addition, some of their constituent components have been described to exert an antiviral effect. Considering this, it was hypothesized that treatment with OOS and VS could protect from viral infections. In order to evaluate the impact of OOS and VS on viral infection, lentivirus and retrovirus whose genomes coded for green fluorescent protein were used. In addition, and as a second approach to measure viral infection, a hemagglutinin-tagged form of the mitogen-activated protein kinase ERK5 was also inserted in the retroviral vector. Viral particles produced in 293T cells were used to infect HeLa cells in the presence or absence of OOS or VS. It was observed that VS had a minimal effect on the capacity of either lentivirus or retrovirus to infect HeLa cells. However, OOS significantly reduced the infection of HeLa cells with both of these viruses. The effect was dose-dependent, reaching a maximum at a 1:100 dilution of OOS. These results suggested that, in addition to its well-known antitumoral properties, OOS may also inhibit infection with viruses. This effect is relevant since patients receiving oncological therapies are more susceptible to viral infections, and nutritional supplements such as OOS may help in reducing the severity of these potential pathogenic infections.

show abstract

Viusid, a nutritional supplement, in combination with interferon α‐2b and ribavirin in patients with chronic hepatitis C

Abstract: Our results suggest that triple therapy with Viusid, IFN alpha-2b and ribavirin was well tolerated and may have a beneficial effect on histologic and biochemical variables. The intensity of anemia is reduced in patients treated with Viusid.

Cited by 11 publications

References 56 publications

Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial

Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial

Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease

Ocoxin oral solution demonstrates antiviral properties in cellular models

Contact Info

Product

Resources

About